Our Pricing

Wegovy FlexTouch Pen UK Prescription

Published on: June 03, 2026

The wegovy flextouch pen uk prescription service at Cured Pharmacy connects you with UK-registered prescribers who assess your suitability for semaglutide weight loss treatment from £79.00. Our streamlined online consultation takes under three minutes, with discreet home delivery of genuine UK-licensed Wegovy pens once approved.

How Wegovy FlexTouch Pens Work for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 in your body [1]. The FlexTouch pen delivers a precise weekly subcutaneous dose that works on multiple pathways: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and improves blood sugar regulation.

In the landmark STEP 1 clinical trial, participants using Wegovy 2.4 mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. The FlexTouch delivery system ensures consistent dosing with a pre-filled, single-use pen that requires no mixing or preparation.

Wegovy is licensed by the MHRA for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. Your UK prescriber will verify eligibility during your online assessment.

Wegovy Dosing Schedule and FlexTouch Pen Strengths

The Wegovy treatment protocol follows a gradual dose escalation over 16 weeks to minimise gastrointestinal side effects [2]. You begin with 0.25 mg weekly for four weeks, then increase monthly through 0.5 mg, 1 mg, and 1.7 mg doses before reaching the maintenance dose of 2.4 mg weekly.

Each FlexTouch pen is colour-coded and pre-filled with a single dose. The pen features a clear dose counter, ergonomic grip, and hidden needle that auto-retracts after injection. Most patients inject into the abdomen, thigh, or upper arm, rotating sites weekly to reduce injection site reactions.

What to Expect During Dose Escalation

The gradual titration allows your body to adapt to semaglutide's effects. Mild nausea, constipation, or diarrhoea may occur during the first 4-8 weeks but typically resolve as you adjust [2]. If side effects persist beyond two weeks at any dose level, your prescriber may recommend staying at your current dose for an additional month before escalating.

Clinical Evidence: STEP Trial Programme Results

The STEP clinical trial programme evaluated semaglutide 2.4 mg across diverse populations. STEP 1 enrolled 1,961 adults without diabetes and demonstrated that 86.4% of Wegovy users achieved at least 5% weight loss, whilst 69.1% lost 10% or more of their baseline weight [1].

STEP 2 specifically examined patients with type 2 diabetes, showing an average 9.6% weight reduction alongside improved glycaemic control with HbA1c reductions of 1.6 percentage points [3]. STEP 3 combined Wegovy with intensive behavioural therapy, producing an average 16.0% weight loss over 68 weeks [3].

Long-term data from STEP 4 revealed that participants who stopped Wegovy regained approximately two-thirds of lost weight within 52 weeks, whilst those who continued treatment maintained their weight loss [4]. This underscores that Wegovy is a long-term therapy requiring ongoing treatment for sustained results.

Real-World Effectiveness Beyond Trials

Post-marketing surveillance in UK clinical practice shows similar effectiveness to trial data when patients adhere to weekly injections and maintain regular prescriber follow-up. The MHRA continues to monitor safety signals, with the most common reported adverse events remaining gastrointestinal in nature and typically mild to moderate in severity.

Wegovy FlexTouch Pen UK Prescription Process at Cured Pharmacy

Obtaining your wegovy flextouch pen uk prescription begins with our online medical questionnaire, which takes under three minutes to complete. You'll provide information about your current weight, height, medical history, existing medications, and any previous weight loss attempts.

A UK-registered prescriber from our clinical team reviews your assessment within 24 hours. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical decisions, ensuring every prescription meets MHRA guidelines and NICE recommendations for weight management [5]. If approved, your prescription is issued and sent to our dispensary for fulfillment.

We dispatch Wegovy FlexTouch pens in 100% discreet packaging with next-day delivery options across the UK. Each shipment includes patient information leaflets, sharps disposal guidance, and access to our pharmacist support line at (+44) 116 4646009 for any questions during your treatment.

Managing Side Effects and When to Contact Your Prescriber

Gastrointestinal side effects affect approximately 44% of Wegovy users during the first 12 weeks, with nausea being most common [2]. These symptoms typically peak 2-3 days after injection and diminish as your body adapts. Eating smaller, more frequent meals and avoiding high-fat foods can reduce discomfort.

Rare but serious side effects include pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, and hypoglycaemia in patients taking other diabetes medications [2]. Contact your prescriber immediately if you experience persistent severe abdominal pain, jaundice, or signs of an allergic reaction such as facial swelling or difficulty breathing.

Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [2]. It remains contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Optimising Your Treatment Journey

Combining Wegovy with a reduced-calorie diet and increased physical activity produces optimal results. NICE guidelines recommend at least 150 minutes of moderate-intensity exercise weekly alongside nutritional counseling [5]. Your prescriber will arrange follow-up assessments every 12 weeks to monitor weight loss progress, side effects, and ongoing suitability for treatment.

Wegovy Pricing and Why Cured Pharmacy Offers the Lowest UK Rates

At Cured Pharmacy, Wegovy FlexTouch pens start from £79.00, reduced from the standard £79.00 rate. This transparent upfront pricing includes your UK prescriber consultation, prescription issuance, and dispensing by our GPhC-registered pharmacy (9012511). There are no hidden fees or subscription charges.

We maintain the lowest prices guaranteed in the UK through our direct relationships with licensed wholesalers and efficient online-first model. Every Wegovy pen is sourced from UK-licensed suppliers and stored in our temperature-controlled facilities to ensure product integrity. You'll see the exact cost before completing your medical assessment, with no obligation to proceed if the price doesn't suit your budget.

Monthly costs vary depending on your prescribed dose during the escalation phase. Most patients reach the maintenance 2.4 mg dose by week 17, at which point you'll require four pens per 28-day cycle. Our pharmacist team can discuss payment plans and answer pricing questions via phone or our online chat service.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults meeting specific BMI criteria. Individual results may vary. Side effects can occur; read the patient information leaflet carefully.